

Neuropeptide S (human)

Cat. No.:	HY-P1389
CAS No.:	412938-67-1
Molecular Formula:	C ₉₃ H ₁₅₅ N ₃₁ O ₂₈ S
Molecular Weight:	2187.5
Sequence:	Ser-Phe-Arg-Asn-Gly-Val-Gly-Thr-Gly-Met-Lys-Lys-Thr-Ser-Phe-Gln-Arg-Ala-Lys-Ser
Sequence Shortening:	SFRNGVGTGMKKTFSFQRAKS
Target:	Others
Pathway:	Others
Storage:	Sealed storage, away from moisture and light, under nitrogen
	Powder -80°C 2 years
	-20°C 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

BIOLOGICAL ACTIVITY

Description	Neuropeptide S human, a neuropeptide, is a potent cognate neuropeptide S receptor (NPSR) agonist. Neuropeptide S human can be used for Alzheimer's disease (AD) research ^[1] .								
IC₅₀ & Target	EC ₅₀ : 9.4 nM (neuropeptide S receptor) ^[1]								
In Vitro	<p>Half-maximal effective concentrations (EC₅₀) for mobilization of [Ca²⁺]_i are 9.4 nM, 3.2 nM, and 3.0 nM for human, rat, and mouse Neuropeptide S (NPS), respectively^[1].</p> <p>Neuropeptide S human (4 pM to 1.7 nM; 48 hours) retains full agonist activity with an EC₅₀ of 6.7 nM, the binding of [¹²⁵I] Y10-hNPS to CHO cells stably expressing hNPSR is saturable with high affinity (K_d = 0.33 nM)^[1].</p> <p>Neuropeptide S human (1 pM-3 μM; 48 hours) are used to compete with 0.15 nM [¹²⁵I] Y10-NPS, [¹²⁵I] Y10-NPS is displaceable by increasing concentrations of human NPS (IC₅₀ = 0.42 nM)^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>Neuropeptide S human (0.1 nM-1 nM; i.c.v.) causes a significant increase in locomotor activity, the total distance traveled, percentage of time moving, number of rearing events, and center entries are also significantly increased in mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male C57Bl/6 mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.1 nM, 1 nM</td> </tr> <tr> <td>Administration:</td> <td>Intracerebroventricular (i.c.v.) injection</td> </tr> <tr> <td>Result:</td> <td>Increased locomotor activity and promoted wakefulness.</td> </tr> </table>	Animal Model:	Male C57Bl/6 mice ^[1]	Dosage:	0.1 nM, 1 nM	Administration:	Intracerebroventricular (i.c.v.) injection	Result:	Increased locomotor activity and promoted wakefulness.
Animal Model:	Male C57Bl/6 mice ^[1]								
Dosage:	0.1 nM, 1 nM								
Administration:	Intracerebroventricular (i.c.v.) injection								
Result:	Increased locomotor activity and promoted wakefulness.								

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA